RGX-104
- RGX 104；RGX104；CPD1632
货号： abs814489
| 货号-规格 | 货期 | 价格 | 数量 |
| abs814489-5mg | 1-2周 | ￥1874.00 | - + |
| abs814489-10mg | 1-2周 | ￥3087.00 | - + |
| abs814489-25mg | 1-2周 | ￥6064.00 | - + |
| abs814489-50mg | 1-2周 | ￥9151.00 | - + |
大包装询价| 产品描述 | ||
| 描述 | RGX-104 is a orally bioavailable liver X receptor agonist that modulates innate immunity via transcriptional activation of the ApoE gene. | |
| 纯度 | ＞98% | |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. | |
| 基本信息 | ||
| 别名 | RGX 104；RGX104；CPD1632 | |
| 外观 | Powder | |
| 可溶性/溶解性 | DMSO : ≥ 125 mg/mL (197.62 mM) | |
| 生物活性 | ||
| 靶点 | LXR | |
| In vitro(体外研究) | RGX-104 is an oral first-in-class LXR agonist that robustly induces ApoE expression resulting in innate-immune mediated anti-tumor activity. RGX-104 drives anti-tumor immunity by regulating the abundance and activity of myeloid derived suppressor cells (MDSC) and dendritic cells (DC). | |
| In vivo(体内研究) | Antitumor activity has been demonstrated with RGX-104 monotherapy in several syngeneic and xenograft tumor models, including melanoma, lung cancer, ovarian cancer, GBM and others. The anti-tumor activity of LXR-agonism is related to constitutive upregulation of ApoE expression. | |
| 温馨提示：本产品仅作科研实验使用，不支持临床等研究 |
- 实验方法 实验条件
共 0 张，还能上传 8 张 提交
- 提示： 尊敬的客户您好，如果您对我们的产品有什么疑问或想要了解的，可以点击“我要咨询”按钮填写您的疑问。
提交不成功？请联系info@absin.cn。
Certificate of Analysis(COA)
促销资讯 更多
订购信息
您可以从我们的授权经销商处购买absin产品或获得技术支持。若要查看您所在地区的经销商，请从以下的下拉列表中选择。
危险品化学品经营许可证(不带存储)
营业执照(三证合一)